UK Pharmacogenetics & Stratified Medicine Network 11th Open Meeting

UK Pharmacogenetics & Stratified Medicine Network 11th Open Meeting



UK Pharmacogenetics & Stratified Medicine Network 11th Open Meeting

At UK Pharmacogenetics & Stratified Medicine Network (UKPGx) 11th Annual Open Meeting (UKPGx2024) you will hear about the latest developments in the field of pharmacogenetics and stratified medicine. Multidisciplinary experts will come together to review, and offer solutions to, the challenges facing the adoption of genomic medicine into the clinic.


Hear about the latest developments in the field of pharmacogenetics and stratifed medicine at the UKPGx Network's Annual Open Meeting! Multidisciplinary experts will come together to review, and offer solutions to, the challenges facing the adoption of genomic medicine into the clinic.

Over the last 10 years the Network has steadily grown to over 1,200 members. It provides a great opportunity for different disciplines to come together and develop productive collaborations. You are most welcome to join the Network, membership is free!


This last year invited experts from academia, healthcare, regulatory and industry sectors came together to discuss Incorporating Pharmacogenetics into Clinical Decision Support Systems and Pharmacogenetics in Drug Discovery. Presentations from these workshops are available on our  website. The presentations from all our past open meetings and workshops provide a wealth of information and can be viewed on the website.

Approved by the Royal Society of Biology for purposes of CPD, this event may be counted as 27 CPD points. 

 

08:00-09:00      Registration and Refreshments
09:00 - 10:40                Session One Opening Plenary Session
Chair: Professor Sir Munir Pirmohamed
09:00 - 09:10 Welcome & introduction: Professor Sir Munir Pirmohamed
09:10 - 09:40 Professor Dame Sue Hill
Accelerating genomic medicine in the NHS
09:40 - 10:10 Professor Nick Wareham
The changing landscape of cohort studies in the UK
10:10 - 10:40 Professor Raghib Ali
Our Future Health and opportunities for pharmacogenomic and precision public health research
10:40 - 11:10 Morning Coffee
11:10 - 12:10 Session Two Early Career Session
Chair: Vicky Chaplin
11:10 - 11:30 Dr Emma Magavern
Pharmacogenomics in Cardiovascular Medicine:
Insights from a British- South Asian cohort
11:30 - 11:50 Dr John McDermott
Developing an Interoperable and Scalable Platform for the 
Implementation of Pharmacogenetics in the NHS 
11:50 - 12:10 Dr Julia Carrasco Zanini Sanchez
Plasma proteomics for screening and prediction of diverse diseases
12:10 - 13:30 Lunch, Exhibitors stand and Discussion Tables 
13:30 - 15:00   Session Three Mendelian Randomisation
Chair: Professor Ann Daly
13:30 - 14:00 Dr Verena Zuber
Mendelian randomisation strengths and limitations
14:00 - 14:30 Professor Aroon Hingorani
Mendelian Randomization and drug development
14:30 - 15:00 Professor Michael Johnson
Single-cell mendelian randomisation analysis for target and biomarker discovery for central nervous system phenotypes
15:00 - 15:30 Afternoon Tea
15:30 - 17:10 Session Four New Technology Platforms
Chair: Dr Karen Spink
15:30 - 16:00 Dr Greet De Baets
AI in target identification and patient stratification
16:00 - 16:30 Professor Julian Knight
Moving to precision medicine in severe infection using host multi-omics 
16:30 - 16:40 Professor Sir Munir Pirmohamed
Event Close and Thank You

Dr John McDermott

Clinical Geneticist, University of Manchester, United Kingdom
Talk Title: Developing an Interoperable and Scalable Platform for the Implementation of Pharmacogenetics in the NHS


Dr John McDermott is a Clinical Geneticist and an NIHR Doctoral Research Fellow at the University of Manchester. He was appointed as the UK’s first Academic Clinical Fellow in Genomic Medicine in 2016. Working at the Manchester Centre for Genomic Medicine (MCGM) his research focuses on the application genetic and genomic technologies in the acute and everyday healthcare settings. As part of the Newman Laboratory he was awarded funding from the National Institute for Health Research (NIHR) to undertake the world’s first trial of a genetic test in the acute setting to avoid hearing loss in neonates. The Pharmacogenetics to Avoid Loss of Hearing (PALOH) trial and other similar projects require extensive collaboration between industry, academia and clinicians. This collaborative approach is encouraged at the MCGM and in 2018 Dr McDermott was awarded the NIHR Clinical Research Network award for outstanding contribution to UK research. In 2015 Dr McDermott was a visiting scholar at the MIT and Harvard Broad Institute where he first worked with large “multi-omic” datasets. In 2018 he was awarded the Vienna Medal by the European Society of Human Genetics for his translational research. He is a University of Manchester alumnus and is passionate about the unique opportunities for population health research across the region.  Dr McDermott is currently an NIHR Doctoral Research Fellow, investigating models for implementing pharmacogenetics within the NHS. (@John_H_McD)
 

Professor Aroon Hingorani


 

Professor of Genetic Epidemiology and Honorary Consultant Physician at UCL and UCL Hospitals, London
Talk Title: Mandelian Randomization and drug development

Aroon Hingorani is UCL Professor of Genetic Epidemiology; former Director of the UCL Institute of Cardiovascular Science (2011-2021); Cardiovascular Programme Lead for the UCL Hospitals NIHR Biomedical Research Centre; Director of the UCL British Heart Foundation Research Accelerator; and Principal Investigator of the UKRI-NIHR-DHSC funded Multimorbidity Mechanisms and Therapeutics Research Collaborative. He is Consultant Physician at University College London Hospitals NHS Foundation Trust with subspecialty accreditation in Clinical Pharmacology and Therapeutics. He chairs the North Central London Joint Formulary Committee and is an NIHR Senior Investigator.
His current work focuses on the use of genetic studies in populations as a tool to identify and validate drug targets, using the Mendelian randomisation principle, to improve efficiency in pharmaceutical development. He also has an interest in critical evaluation of the use of genomic and biomarker data for disease prediction and stratification and in the causes and management of multimorbidity.
Professor Hingorani has been a member of NICE guideline development groups on the prevention of thromboembolism in hospitalised patients and on lipid lowering for the prevention of cardiovascular disease.

 

Professor Michael Johnson DPhil FRACP FRCP



Professor of Neurology and Genomic Medicine at Imperial College London, United Kingdom
Talk Title: Single-cell Mendelian randomization for target and casual biomarker discovery

Professor Johnson is Professor of Neurology and Genomic Medicine at Imperial College London, and Honorary Consultant Neurologist at Imperial College Healthcare. His academic research focuses on systems-level data integration to identify cell-type specific causal genes and biomarkers. His work has resulted in drug target and therapeutic use patent applications, enduring pharma collaborations, and a successful biotech spin-out. He sits on the Executive Management Committee for the Department of Brain Sciences at Imperial College, where he has previously served as Deputy Head of the Division of Clinical Translation and Interim Head of the Division of Neurology. He is Co-Lead for the Advanced Therapeutics theme in the newly created UK Epilepsy Research Institute. His research is funded by the MRC, Parkinson’s UK and several global Pharma including long-term support from UCB and Roche for molecular causal inference. 
 

Professor Julian Knight




Professor of Genomic Medicine, University of Oxford, United Kingdom
Talk Title: Moving to precision medicine in severe infection using host multi-omics

Julian Knight is Professor of Genomic Medicine at the University of Oxford, Director of the Doctoral Training Programme in Genomic Medicine and Statistics, and a Fellow and Tutor in Medicine at Merton College. Since 2005 he has worked at the Wellcome Centre for Human Genetics as a Principal Investigator and as an Honorary Consultant Physician at the Oxford University Hospitals NHS Trust in internal medicine. He is also Research Director of the Central and South Genomic Medicine Services Alliance. His research investigates the genomics of immunity and how this can determine our individual response to infections such as sepsis and development of autoimmunity.

Dr Julia Carrasco - Zanini Sanchez




Postdoctoral Research Assistant In Computational Genomics and Multiomics, Precision Healthcare University Research Institute, London, United Kingdom
Talk Title: Plasma Proteomics For Screening and Prediction of Diverse Disease

Julia Carrasco-Zanini Sanchez is a postdoctoral researcher in computational genomics and multiomics at Queen Mary’s new Precision Healthcare University Research Institute (PHURI).  Julia did her undergraduate degree in Biomedical Sciences at the National Autonomous University in Mexico. She later received her PhD from the University of Cambridge, as part of the Wellcome Trust MRes + PhD programme in Metabolic and Cardiovascular disease. Her thesis focused on the use of broad-capture plasma proteomic technologies for the development of sparse predictive protein signatures and for the identification of candidate causal targets. Julia is now interested in how integration of multiomics with electronic health records can be applied to improve targeted screening, prediction and prognostic strategies for a diverse range of common and rare diseases.
 

Dr Emma Magavern



Clinical Pharmacology Registrar, Queen Mary University, London, United Kingdom
Talk Title: Pharmacogenomics in cardiovascular medicine: insights from a British-South Asian cohort

Dr Magavern is a Clinical Pharmacology Registrar in London and a PhD candidate at the William Harvey Research Institute, QMUL, working with Professor Mark Caulfield. She completed a BA in English prior to her MD and subsequent MScs in Bioethics and Genomics. Through training in clinical medicine, humanities, genetics and pharmacology she has developed an interest in the scientific merits, clinical potential and implementation challenges of pharmacogenomics. She was co-secretary of the RCP/BPS working group on pharmacogenomics and led the ESC pharmacotherapy working group pharmacogenomics position paper. She is part of the newly appointed NHS England Network of Excellence for Pharmacogenomics. 

Professor Dame Sue Hill




Chief Scientific Officer for England, NHS England, United Kingdom
Talk Title: Accelerating Genomic Medicine in the NHS

Professor Dame Sue Hill DBE FMedSci FRSB FRCP(Hon) FRCPath (Hon) FHCS (Hon) is the Chief Scientific Officer (CSO) for England and the Head of Profession for the scientific workforce and provides scientific leadership and advice for the wider health and care system. A respiratory scientist by background, she has an international academic and clinical research reputation. 
As CSO, Dame Sue has been a champion of education and training for the profession, leading the UK wide Modernising Scientific Careers initiative and now the broader NHS diagnostics and cancer workforce and genomics education programmes.
She has led, and continues to lead, large-scale transformation programmes and major policy developments across all levels of the health and care system and across government. Her reputation for championing new ways of working ensures patient outcomes and system improvements are at the heart of her work. 
Dame Sue leads and directs Genomics in the NHS, driving the world-leading programme to introduce a nationwide Genomic Medicine Service working in partnership to deliver cutting edge technologies for patient benefit and establishing new collaborations between the NHS and academia, industry and international governments/initiatives.  This builds on her work in heading up the NHS contribution to the world-leading 100,000 Genomes Project.
She played a major role in the national COVID-19 response programme leading the development and deployment of testing technologies into use for the UK population and co-directing the globally recognised programme for whole-genome sequencing of SARS-CoV-2.
Dame Sue was made a Dame Commander in 2018 in recognition of the scale of her contribution to British genomics, having previously been awarded an OBE in 2005 in recognition of her services to healthcare science. In 20/21 she was named one of The 80 Most Influential People in English NHS and health policy.
 

Professor Raghib Ali







Chief Executive and Chief Medical Officer, Our Future Health
Talk Title: Our Future Health and opportunities for pharmacogenomic and precision public health research

Professor Raghib Ali is the CEO, Chief Investigator and Chief Medical Officer of Our Future Health; a Clinical Epidemiologist at the University of Cambridge; a Consultant in Acute Medicine at the Oxford University Hospitals NHS Trust; and Honorary Consultant with the Office for Health Disparities and Improvement. 
He graduated from Cambridge University and has been awarded postgraduate degrees in Epidemiology and Public Health from the Universities of London, Cambridge and Oxford and is a Fellow of the Royal College of Physicians. He has been involved in population health research since 2004 nationally and globally, working firstly on UK Biobank, then leading studies of cancer incidence by ethnic group in England and India from 2005 to 2013 and established the UAE Healthy Future Study, in 2014, for which he is the principal investigator.
He was awarded an OBE in the Queen's Birthday Honours 2022 for services to the NHS and the Covid-19 response and elected as an Honorary Fellow in the Faculty of Public Health, 'the highest accolade the Faculty can bestow and is awarded to those who have given exceptional service to the science, literature or practice of public health' in April 2023.
 

Dr Nick Wareham




Director, MRC Epidemiology Unit; Co-Director, Institute of Metabolic Science, University of Cambridge
Talk title: The changing landscape of cohort studies in the UK

Nick Wareham is Director of the MRC Epidemiology Unit and Co-Director of the Institute of Metabolic Science, University of Cambridge. He is Chair of the MRC Population Health Sciences Group and has been responsible for reviewing means of supporting the changing landscape of population-based cohorts in the UK.

Verena Zuber





Senior Lecturer in Biostatistics, Imperial College London, UK
Talk title: Mendelian randomisation strengths and limitations

Verena is a Senior Lecturer in Biostatistics at the Department of Epidemiology and Biostatistics at Imperial College, London. Her main research interest is the development of statistical methodology for casual inference and statistical genetics. Her motivation is grounded in translational projects looking into molecular mechanisms, causes of diseases, and how to define efficient intervention and prevention strategies to improve human health.

She has a background in Statistics (MSc, LMU Munich, Germany) and she worked on high-dimensional variable selection for biomarker discovery during her PhD in Biostatistics at the University of Leipzig, Germany. As a research associate, she has gained experience in statistical genetics at the University of Oslo, Norway and at the EBI, Cambridge, UK. Verena then joined the team of Stephen Burgess at the MRC Biostatistics Unit in Cambridge, UK to work on statistical methods for casual inference and in particular, Mendelian randomization. 

 

Professor Sir Munir Pirmohamed



Professor Sir Munir Pirmohamed MB ChB, PhD, FRCPE, FRCP, FBPhS, FMedSci is David Weatherall Chair in Medicine at the University of Liverpool, and a Consultant Physician at the Royal Liverpool University Hospital. He is Director of the Centre for Drug Safety Sciences, and Director of the Wolfson Centre for Personalised Medicine. He is also Director of HDR North. He is an inaugural NIHR Senior Investigator, Fellow of the Academy of Medical Sciences in the UK, Commissioner on Human Medicines. He was President of British Pharmacological Society from January 2020 - December 2021, and is currently President of the Association of Physicians. He was awarded a Knights Bachelor in the Queen's Birthday Honours 2015. His research focuses on personalised medicine, clinical pharmacology and drug safety.

 

We're excited to unveil our partnership opportunities! For more information on how to participate please download our - Partnership Prospectus 

If you have any questions or wish to connect with a member of the events team, please contact meetings@bps.ac.uk.
 

Confirmed Partners

                           























                            
                                 

The Royal College of Physicians building is situated on St Andrews Place opposite Regent’s Park. They are a five-minute walk from Regent’s Park station or Great Portland Street station. They have a lift platform for wheelchair access at the entrance.



There are a great range of 3, 4 and 5 star hotels in close proximity to RCP London Events. Their recommended hotel booking agent has negotiated discounted rates with local hotels for both individuals and group bookings. For more information and for a list of current hotels and rates, please contact:
Jen Herbert
Diversity Travel
Tel: 0161 235 5413
Email: rcpevents@diversitytravel.com

Royal College of Physicians 
11 St Andrews Place
Regent's Park
London
NW1 4LE

 

Tickets


Early Career Researcher Non-Member Ticket £50.00
General Registration Non-Member Ticket £115.00
Industry Registration Non-Member Ticket £265.00
From
26 June 2024
To
26 June 2024
Venue
Royal College of Physicians 11 St Andrews Place Regent's Park London




Connect with us:

© 2021 British Pharmacological Society, The Schild Plot, 16 Angel Gate, City Road, London EC1V 2PT, United Kingdom

loading